Why Is EyePoint Pharmaceuticals Stock Plummeting On Monday?
Posted
Vandana Singh (via Benzinga)
EyePoint Pharmaceuticals reveals Phase 2 PAVIA trial results for Duravyu in non-proliferative diabetic retinopathy. Positive data showcases Duravyu's efficacy and safety profile.
read more
Biotech,
Briefs,
EYPT,
News,
Stories That Matter,
why it's moving,
Health Care,
Top Stories,
Movers,
General,
EYPT,
News,
Biotech,
Health Care,
Top Stories,
Movers,
General,
Benzinga
